期刊文献+

环胞菌素A治疗难治性贫血7例临床观察

Clinical Report on Treatment of 7 Patients with Refractory Anemia by Using Cyclosporin A
下载PDF
导出
摘要 为了探讨难治性贫血治疗 ,对 7例骨髓增生异常综合征 (难治性贫血亚型 )患者 ,应用环胞菌素A(CsA)和康力龙进行了治疗 ,CsA用药时间为 5个月至 3年 ,平均为 13个月。结果表明 :6例治疗有效 ,1例无效。治疗有效的 6例中 3例完全缓解 ,不依赖输血 ,1例获得部分缓解 ,2例有所好转。治疗好转时间为 1- 5个月 ,平均为 3 5月。在观察期间所有病例无白血病或其它肿瘤临床表现。结论 :环胞菌素A对部分难治性贫血病例有效 ,患者对毒副作用可耐受 ,值得进一步观察应用。 To explore the treatment of refractory anemia (RA), 7 cases of myelodysplastic s yndrome (subtype of refractory anemia) were treated in combination of cyclosporin A (CsA) with st anozolol. Duration of treatment with CsA was 5 months - 3 years (mean 13 months ). The results showed that anmong 7 cases 6 were effective, 1 case no responded to treatment. 3 cases out of 6 effective cases achieved complete remission with out transfusion dependence, 1 cases achieved partial remission, 2 cases were imp roved. During the investigation signs of leukemia ot other malignant tumors not were found in all cases. In conclusion, CsA treatment is effective for part cas es of RA, side effects of drugs are tolerable for patients.
出处 《中国实验血液学杂志》 CAS CSCD 2004年第5期697-698,共2页 Journal of Experimental Hematology
关键词 骨髓增生异常综合症 难治性贫血 环胞菌素A myelodysplastic syndrome refractory anemia cyclo sporin
  • 相关文献

参考文献4

  • 1Shimamoto T, Ohyashiki K. Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma, 2003; 44:593 - 604
  • 2Jonasova A, Neuwirtova K, Cermak J, et al. Cyclosporin A thera py in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol, 1998; 100:304 309
  • 3Enright H, Jacob HS, Vercelloti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol, 1995; 91:403 - 408
  • 4管梅.环孢菌素A在骨髓增生异常综合征中的应用[J].中国实验血液学杂志,2003,11(6):678-680. 被引量:10

二级参考文献23

  • 1[1]Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anemias without hypoplastic bone marrow. Brit J Haematol, 1998;100:304-309
  • 2[2]Catalano L, Selleri C, Luciano L, et al. Prolonged response to cyclosporin A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica, 2000; 85:133-138
  • 3[4]Shimamoto T, Iguchi T, Kacagiri T, et al. Successful treatment with Cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. British Journal of Haematology, 2001; 114:358-361
  • 4[5]Y. Asano, M. Maeda, N. Uchida, et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol, 2001; 80:634-638
  • 5[6]John MB, New York: Marcel Oekker, Inc. The myelodysplastic Syndroms: pathobiology and clinical managements. 2002:121-138
  • 6[7]Yogen S, JeffereyJ M, Mary R, et al. Conincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. British Journal of Haematology, 2001;112:195-200
  • 7[8]Biesma DH, van de Twell JG, Vendonch LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer, 1997;79:548-551
  • 8[9]Grigg AP, O'Flaherty E. Cyclosporin A for the treatment of pure red cell aplasia associated with Myelodysplasia. Leukemia & Lymphoma, 2001; 42:1339-1342
  • 9[10]Samuelsson J, Larfars G. Unusual clinical presentation in a patient with myelodysplastic syndrome, with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A, erythropoietin and granulocyte colony-stimlating factor. Leuk Res, 1999; 23:513-517
  • 10[11]Kusumoto S, Jinnai I, Matsuda A, et al. Bone marrow patterns in patients with aplastic anemia and myelodysplastic syndrome: observations with magnetic resonance imaging. Eur J Hematol, 1997; 59:155-161

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部